Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Yarrow Bioscience (NASDAQ:YARW – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.
Insider and Institutional Ownership
21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 83.8% of Yarrow Bioscience shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Capricor Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, Yarrow Bioscience has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| Yarrow Bioscience | 1 | 0 | 2 | 0 | 2.33 |
Capricor Therapeutics currently has a consensus target price of $30.25, indicating a potential upside of 219.29%. Yarrow Bioscience has a consensus target price of $58.00, indicating a potential upside of 157.55%. Given Capricor Therapeutics’ higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Yarrow Bioscience.
Profitability
This table compares Capricor Therapeutics and Yarrow Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -56.60% | -43.97% |
| Yarrow Bioscience | -4,726.21% | -84.40% | -77.68% |
Earnings and Valuation
This table compares Capricor Therapeutics and Yarrow Bioscience”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 24.73 | -$105.04 million | ($2.45) | -3.87 |
| Yarrow Bioscience | $570,000.00 | 105.49 | -$26.48 million | ($14.64) | -1.54 |
Yarrow Bioscience has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Yarrow Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Capricor Therapeutics beats Yarrow Bioscience on 8 of the 14 factors compared between the two stocks.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About Yarrow Bioscience
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
